Company: RENEF
Filing Date: 2025-10-08
Form Type: PRE 14A
Source: 0001104659-25-097940
Chunk: 60

Company: Cartesian Growth Corp II
Filing Date: 2025-10-08
Form: PRE 14A
Chunk 60
---
 the Company’s directors, officers, advisors or any of their respective
affiliates purchase public shares in situations in which the tender offer rules restrictions on purchases would apply, they (a) would
purchase the public shares at a price no higher than the price offered through the Company’s redemption process (i.e., approximately
$[ ] per share, based on the amounts held in the Trust Account as of October [
], 2025; (b) would represent in writing that such public shares will not be voted in favor of approving the Extension; and (c) would
waive in writing any redemption rights with respect to the public shares so purchased.

<div align='center'>30</div>

To the extent any such purchases
by the Sponsor, the Company’s directors, officers, advisors or any of their respective affiliates are made in situations in which
the tender offer rules restrictions on purchases apply, the Company will disclose in a Current Report on Form 8-K prior to the Extraordinary
General Meeting the following: (i) the number of public shares purchased outside of the redemption offer, along with the purchase price(s)
for such public shares; (ii) the purpose of any such purchases; (iii) the impact, if any, of the purchases on the likelihood that the
Extension will be approved; (iv) the identities of the securityholders who sold to the Sponsor, the Company’s directors, officers,
advisors or any of their respective affiliates (if not purchased on the open market) or the nature of the securityholders (e.g., 5% security
holders) who sold such public shares; and (v) the number of Ordinary Shares for which the Company has received redemption requests pursuant
to its redemption offer.

The purpose of such share
purchases and other transactions would be to increase the likelihood of otherwise limiting the number of public shares electing to redeem.

If such transactions are
effected, the consequence could be to cause the Extension to be effectuated in circumstances where such effectuation could not otherwise
occur. Consistent with SEC guidance, purchases of shares by the persons described above would not be permitted to be voted for the Extension
at the Extraordinary General Meeting and could decrease the chances that the Extension would be approved. In addition, if such purchases
are made, the public “float” of our securities and the number of beneficial holders of our securities may be reduced, possibly
making it difficult to maintain or obtain the quotation, listing or trading of our securities on a